Vermillion Inc. announced publication of a paper titled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (Shulman et al. Adv Ther. July 2019).
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
